Holderness Investments Co. purchased a new position in Sanofi SA (NYSE:SNY) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 4,570 shares of the company’s stock, valued at approximately $204,000.
A number of other institutional investors have also recently made changes to their positions in SNY. FMR LLC grew its holdings in Sanofi by 7.5% in the 3rd quarter. FMR LLC now owns 8,527,983 shares of the company’s stock worth $380,945,000 after acquiring an additional 595,125 shares during the last quarter. Alliancebernstein L.P. grew its holdings in Sanofi by 617.8% in the 3rd quarter. Alliancebernstein L.P. now owns 306,090 shares of the company’s stock worth $13,673,000 after acquiring an additional 263,445 shares during the last quarter. American Century Companies Inc. bought a new stake in Sanofi in the 2nd quarter worth $7,602,000. OLD Mission Capital LLC bought a new stake in Sanofi in the 2nd quarter worth $7,189,000. Finally, Bank of New York Mellon Corp grew its holdings in Sanofi by 15,317.9% in the 3rd quarter. Bank of New York Mellon Corp now owns 156,183 shares of the company’s stock worth $6,976,000 after acquiring an additional 155,170 shares during the last quarter. 7.34% of the stock is currently owned by institutional investors and hedge funds.
In other news, major shareholder Sanofi sold 104,552 shares of the firm’s stock in a transaction dated Thursday, September 6th. The shares were sold at an average price of $406.68, for a total value of $42,519,207.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.00% of the company’s stock.
NYSE:SNY opened at $44.92 on Monday. Sanofi SA has a 12 month low of $37.43 and a 12 month high of $46.25. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.22 and a quick ratio of 0.85. The stock has a market capitalization of $112.66 billion, a PE ratio of 14.35, a P/E/G ratio of 2.55 and a beta of 0.70.
Sanofi (NYSE:SNY) last posted its earnings results on Wednesday, October 31st. The company reported $1.07 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.98 by $0.09. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The firm had revenue of $9.39 billion during the quarter, compared to analysts’ expectations of $9.10 billion. During the same period last year, the company posted $1.71 EPS. The company’s quarterly revenue was up 1.5% compared to the same quarter last year. As a group, research analysts forecast that Sanofi SA will post 3.09 earnings per share for the current year.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Read More: Stock Selection – What is cash flow?
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.